Skip to main content
SpringerLink
Log in

Kombinierte HER2-Blockade beim frühen Mammakarzinom langfristig verträglich

  • Gynäkoonkologie
  • Literatur kompakt
  • Published:
Im Focus Onkologie Aims and scope

Die duale HER2-Blockade mit Trastuzumab und Pertuzumab neoadjuvant zusätzlich zur Chemotherapie ist bei Frauen mit frühen, lokal fortgeschrittenen HER2-positivem Mammakarzinom wirksam tolerabel. Die 5-Jahres-Daten der Studie TRYPHAENA bestätigen nun die Effektivität.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Schneeweiss A et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27–35

    Article  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Friederike Klein

Authors
  1. Friederike Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klein, F. Kombinierte HER2-Blockade beim frühen Mammakarzinom langfristig verträglich. Im Focus Onkologie 21, 24–25 (2018). https://doi.org/10.1007/s15015-018-4217-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-018-4217-2

Search

Navigation